2.85

1.42% 0.04

Cardiff Oncology Inc (CRDF)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cardiff Oncology Inc stock is traded at $2.85, with a volume of 1.95M. It is up +1.42% in the last 24 hours and down -29.63% over the past month. Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Previous Close:

$2.81

Open:

$2.81

24h Volume:

1.95M

Relative Volume:

1.66

Market Cap:

$185.60M

Revenue:

$488.00K

Net Income/Loss:

$-41.44M

P/E Ratio:

-3.0645

EPS:

-0.93

Net Cash Flow:

$-31.47M

1W Performance:

+19.75%

1M Performance:

-29.63%

6M Performance:

+2.15%

1Y Performance:

-36.67%

1-Day Range:

$2.73

$2.8874

1-Week Range:

$2.36

$3.0399

52-Week Range:

$2.01

$5.6395

Cardiff Oncology Inc Stock (CRDF) Company Profile

Name

Cardiff Oncology Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

858-952-7570

Address

11055 FLINTKOTE AVENUE, SAN DIEGO, CA

Employee

Twitter

@cardiffoncology

Next Earnings Date

2024-10-31

Latest SEC Filings

CRDF's Discussions on Twitter

Compare CRDF with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRDF Cardiff Oncology Inc	2.85	185.60M	488.00K	-41.44M	-31.47M	-0.93
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-06-24	Initiated	Craig Hallum	Buy
Jan-05-22	Initiated	William Blair	Outperform
Dec-08-21	Initiated	Robert W. Baird	Outperform
Aug-09-21	Resumed	Maxim Group	Buy
Oct-22-20	Initiated	H.C. Wainwright	Buy
Oct-08-20	Initiated	Piper Sandler	Overweight

View All

Cardiff Oncology Inc Stock (CRDF) Latest News

Apr 16, 2025

Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap touched US$186m last week, benefiting both individual investors who own 56% as well as institutions - simplywall.st

Apr 16, 2025

Apr 15, 2025

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing R - GuruFocus

Apr 15, 2025

Cardiff Wraps Up Enrollment in Phase 2 Trial of Prospective Colorectal Cancer Treatment - MarketScreener

Apr 15, 2025

Cardiff Oncology Announces Completion of Enrollment in Phase 2 C - GuruFocus

Apr 15, 2025

Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial i - GuruFocus

Apr 15, 2025

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CRDF Stock News - GuruFocus

Apr 15, 2025

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

Apr 15, 2025

Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial in Colorectal Cancer | CRDF Stock News - GuruFocus

Apr 15, 2025

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 15, 2025

Cardiff Oncology Awards Strategic Compensation Package: Inside the Latest Employee Stock Options Grant - Stock Titan

Apr 15, 2025

Cardiff Oncology Announces Completion of Enrollment in - GlobeNewswire

Apr 15, 2025

Major Progress: First-line Colorectal Cancer Treatment Trial Hits Key Milestone - Stock Titan

Apr 15, 2025

Apr 14, 2025

Cardiff Oncology announces positive colorectal data and $40m stock oversubscription - MSN

Apr 14, 2025

Piper Sandler raises Cardiff Oncology stock target to $10 By Investing.com - Investing.com Canada

Apr 14, 2025

Raymond James Financial Inc. Takes Position in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Apr 14, 2025

American Century Companies Inc. Raises Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Apr 14, 2025

Apr 11, 2025

Metastatic Prostate Cancer Market Future Business - openPR.com

Apr 11, 2025

Apr 05, 2025

HighTower Advisors LLC Grows Position in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Apr 05, 2025

Apr 03, 2025

Lucid Capital Markets sets $14 target on Cardiff Oncology stock By Investing.com - Investing.com Canada

Apr 03, 2025